Clarifying the Natural History of Transthyretin Cardiac Amyloidosis: Insights From the ATTRibute-CM Trial Tools Drug Interaction Checker Pill Identifier Calculators Formulary Slideshow 15 Fingernail and Toenail Abnormalities Overview Presentation History Physical Examination Show All DDx Workup Treatment...
Heart failure (HF) refers to a complex condition resulting from the structural and/or functional inability of the heart to supply a normal cardiac output to meet metabolic needs. In HF, impaired ventricular filling or ejection of blood leads to fatigue , dyspnea , and fluid retention or edema...
High-risk surgery (risk of cardiac death or myocardial infarction (MI) greater than 5 %): emergent major operations (particularly in the elderly), aortic and peripheral vascular surgery, prolonged surgical procedures associated with large fluid shifts and/or blood loss. Intermediate-risk surgery (ri...
2. The spectrum of MGRS-related diseases is shown below (Fig. 3). Amyloidosis was most prevalent, followed by monoclonal immunoglobulin deposition disease (MIDD). Notably, patients whose pathological diagnosis did not meet the classification of MGRS but did show monotypical light-chain deposits in...
Finally, we compared the clinical presentation of patients with the mutation c.210delC and all other G6PC3-deficient patients reported in the literature, and we found that the c.210delC carriers display all prominent clinical features observed in prior patients. In conclusion, G6PC3 c.210...
Cardiac magnetic resonance (CMR) has changed the management of suspected viral myocarditis by providing a ‘positive’ diagnostic test and has lead to new insights into myocardial involvement in systemic inflammatory conditions. In this review we analyse the use of CMR tissue characterisation techniques...
Cardiac amyloidosis [cardiology]—predicting the cardiomyopathies Huda et al. attempted to identify patients at risk of cardiac amyloidosis, a now treatable condition predisposing to heart failure, using various cohorts and established medical diagnoses retrieved from health records25. Using data from 21...
Efficacy and safety of daratumumab monotherapy in newly diagnosed patients with stage 3B light-chain amyloidosis: A Phase 2 study by the European Myeloma Network Abstract #P959 Ciltacabtagene autoleucel vs standard of care in patients ...
Cardiac amyloidosis is among the comparatively frequent systemic diseases in secondary HFpEF. It results from misfolded proteins that accumulate in various organs: light-chain proteins in AL amyloidosis [35] and transthyretin either in wild-type (ATTRwt) or hereditary (ATTRh) amyloidosis. Diagnostic ...
Light-chain amyloidosis Light-chain amyloidosis (AL) is caused by the misfolding of immunoglobulin LCs. A study using cryo-electron microscopy to demonstrate the structure of λ1-AL amyloid fibrils showed thatN-glycosylation acts as a key regulator in fibrin misfolding.192A study using MASS-FIX...